secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0001104659-24-108583
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CAMP4 Therapeutics adopts post-IPO charter authorizing 175M common shares and eliminating written consent
--------------------------------------------------------------------------------

- Fifth amended charter effective Oct 15, 2024; authorizes 175M shares of common stock and 25M shares of undesignated preferred stock.
- Eliminates all references to previously existing series of preferred stock and removes stockholder ability to act by written consent.
- Amended bylaws establish procedures for stockholder proposals and director nominations, and modify officer/director indemnification provisions.
- Charter and bylaw changes were approved by board and stockholders prior to IPO consummation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000110465924108583/0001104659-24-108583-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000110465924108583/tm2426167d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-108583

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer